Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Morphosys GmbH is currently navigating 4 pending office actions within the Biotechnology & Pharmaceuticals sector. These actions are spread across 4 distinct examiners, meaning each examiner is responsible for a pending matter. The workload is divided between 2 distinct art units, suggesting technical specialization in the prosecution process. MCCOLLUM, ANDREA K is identified as the busiest examiner with 1 pending office action.
Since the busiest examiner pending count of 1 is equal to the count for all other distinct examiners, the portfolio's management is distributed. This arrangement prevents any single examiner from managing more than one of the company's 4 pending biotechnology and pharmaceutical actions. The involvement of 2 distinct art units suggests that the company's technology is being evaluated by different technical sections of the patent office. MCCOLLUM, ANDREA K is one of the 4 distinct examiners handling the pending office actions. This structure requires the company to manage interactions with 4 different examiners across 2 separate art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, MICHAEL D | 1 | 58.3% | +30.4% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| LU, CHENG | 1 | 54.1% | +64.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19363223 | ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY | PAK, MICHAEL D | — |
| 18291283 | COMBINATIONS OF ANTIGEN BINDING MOLECULES | HUYNH, PHUONG N | — |
| 18246052 | NOVEL HUMAN ANTIBODIES BINDING TO HUMAN CD3 EPSILON | LU, CHENG | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19363223 | ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY | PAK, MICHAEL D | 1674 | §112DP | Final Rejection | — | Pending | Oct 20, 2025 |
| 18291283 | COMBINATIONS OF ANTIGEN BINDING MOLECULES | HUYNH, PHUONG N | — | §112Other | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18246052 | NOVEL HUMAN ANTIBODIES BINDING TO HUMAN CD3 EPSILON | LU, CHENG | 1642 | §112 | Non-Final OA | — | Pending | Mar 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial